Stock listing
NASDAQ:MNPR Monopar Therapeutics Inc. Stock
Home listing (NASDAQ) of Monopar Therapeutics Inc.
Follow Monopar Therapeutics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:MNPR
$69.00 USD -1.75 (-2.5%)
Close on Nov 20, 2026
- Day range
- $67.36 – $69.86 USDNov 20, 2026
- Volume
- 132,610 sharesNov 20, 2026
- Market cap
- $467.6M USDAt the close on Nov 20, 2026 · price × 6.78M shares outstanding
- 52-week range
- $50.07 – $124.82 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $13.31M USDMedian day 135,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MNPR · Home | $69.00 USD | -1.75 (-2.5%) | 132,610 | $68.50 | $69.86 | $67.36 | $70.75 | Close on Nov 20, 2026 |
| Frankfurt:1IY0 | €62.00 EUR | -1.20 (-1.9%) | — | €62.00 | €62.10 | €62.00 | €63.20 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MNPR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $69.00 | -1.75 | -2.5% | $68.50 | $69.86 | $67.36 | 132,610 | |
| $70.75 | -0.31 | -0.4% | $70.08 | $72.79 | $70.08 | 102,019 | |
| $71.06 | -0.91 | -1.3% | $71.45 | $72.92 | $69.79 | 122,983 | |
| $71.97 | -0.03 | 0.0% | $72.55 | $75.09 | $70.34 | 200,030 | |
| $72.00 | -0.68 | -0.9% | $72.93 | $73.48 | $67.70 | 203,206 | |
| $72.68 | +0.95 | +1.3% | $70.11 | $74.69 | $67.12 | 313,024 | |
| $71.73 | -0.05 | -0.1% | $72.87 | $72.87 | $70.80 | 157,459 | |
| $71.78 | -1.97 | -2.7% | $72.45 | $75.59 | $70.21 | 88,064 | |
| $73.75 | +2.33 | +3.3% | $74.75 | $82.51 | $69.67 | 124,852 | |
| $71.42 | +4.20 | +6.2% | $68.02 | $72.25 | $67.45 | 92,947 | |
| $67.22 | -5.59 | -7.7% | $72.45 | $73.28 | $66.91 | 157,518 | |
| $72.81 | +2.92 | +4.2% | $70.13 | $74.02 | $70.09 | 189,611 | |
| $69.89 | +3.61 | +5.4% | $66.74 | $70.07 | $66.29 | 154,089 | |
| $66.28 | -4.04 | -5.7% | $70.02 | $70.26 | $65.01 | 218,899 | |
| $70.32 | -1.59 | -2.2% | $71.36 | $72.76 | $69.35 | 197,763 | |
| $71.91 | -1.48 | -2.0% | $73.90 | $75.29 | $70.65 | 163,098 | |
| $73.39 | +1.55 | +2.2% | $72.04 | $73.39 | $69.94 | 187,362 | |
| $71.84 | +1.30 | +1.8% | $72.00 | $73.99 | $70.20 | 135,923 | |
| $70.54 | -0.11 | -0.2% | $71.01 | $71.85 | $69.34 | 79,014 | |
| $70.65 | -1.93 | -2.7% | $71.84 | $71.84 | $69.48 | 95,500 | |
| $72.58 | +0.23 | +0.3% | $71.83 | $73.13 | $71.22 | 117,400 | |
| $72.35 | -1.88 | -2.5% | $73.47 | $75.08 | $70.95 | 87,300 | |
| $74.23 | +2.76 | +3.9% | $72.20 | $74.90 | $71.95 | 86,600 | |
| $71.47 | +2.20 | +3.2% | $70.10 | $72.32 | $69.71 | 67,600 | |
| $69.27 | -2.53 | -3.5% | $71.01 | $71.01 | $68.81 | 161,600 | |
| $71.80 | -1.30 | -1.8% | $73.20 | $73.28 | $70.05 | 140,900 | |
| $73.10 | +1.02 | +1.4% | $70.74 | $74.01 | $70.51 | 129,600 | |
| $72.08 | -4.97 | -6.5% | $76.16 | $76.92 | $71.66 | 249,900 | |
| $77.05 | -1.91 | -2.4% | $79.30 | $79.59 | $75.05 | 128,500 | |
| $78.96 | -5.02 | -6.0% | $83.47 | $84.04 | $78.80 | 135,800 | |
| $83.98 | +0.20 | +0.2% | $82.48 | $85.49 | $81.27 | 185,500 | |
| $83.78 | +4.21 | +5.3% | $78.28 | $85.03 | $77.98 | 107,000 | |
| $79.57 | +1.28 | +1.6% | $78.04 | $82.66 | $75.33 | 302,200 | |
| $78.29 | +0.32 | +0.4% | $78.72 | $79.59 | $76.24 | 128,300 | |
| $77.97 | 0.00 | 0.0% | $78.36 | $80.00 | $77.03 | 107,600 | |
| $77.97 | -1.70 | -2.1% | $79.64 | $80.33 | $77.59 | 130,800 | |
| $79.67 | -0.33 | -0.4% | $80.00 | $82.35 | $79.33 | 226,300 | |
| $80.00 | -3.72 | -4.4% | $82.77 | $83.04 | $79.38 | 162,400 | |
| $83.72 | -1.515 | -1.8% | $85.24 | $86.69 | $82.92 | 268,200 | |
| $85.24 | -3.605 | -4.1% | $89.58 | $90.00 | $85.06 | 105,800 | |
| $88.84 | -0.54 | -0.6% | $88.03 | $90.05 | $86.54 | 252,900 | |
| $89.38 | -7.25 | -7.5% | $96.78 | $96.78 | $87.59 | 89,300 | |
| $96.63 | +0.91 | +1.0% | $96.60 | $97.37 | $94.01 | 136,000 | |
| $95.72 | -0.75 | -0.8% | $97.92 | $98.19 | $94.95 | 89,200 | |
| $96.47 | -6.23 | -6.1% | $102.44 | $102.45 | $95.96 | 382,800 | |
| $102.70 | +1.25 | +1.2% | $103.33 | $104.09 | $98.90 | 206,600 | |
| $101.45 | -2.88 | -2.8% | $105.48 | $105.49 | $100.13 | 89,600 | |
| $104.33 | -3.99 | -3.7% | $106.93 | $106.93 | $101.89 | 91,800 | |
| $108.32 | -1.94 | -1.8% | $111.99 | $111.99 | $107.02 | 106,600 | |
| $110.26 | +0.30 | +0.3% | $113.84 | $113.84 | $109.77 | 90,000 | |
| $109.96 | -2.42 | -2.2% | $110.55 | $112.56 | $108.84 | 89,500 | |
| $112.38 | -2.00 | -1.7% | $112.31 | $116.61 | $112.19 | 110,300 | |
| $114.38 | -3.18 | -2.7% | $115.61 | $117.61 | $113.27 | 103,900 | |
| $117.56 | -0.99 | -0.8% | $117.85 | $119.00 | $116.21 | 81,400 | |
| $118.55 | +2.27 | +2.0% | $117.44 | $121.02 | $115.07 | 208,600 | |
| $116.28 | -1.29 | -1.1% | $119.04 | $121.00 | $114.28 | 203,300 | |
| $117.57 | +5.64 | +5.0% | $110.21 | $118.00 | $110.21 | 95,200 | |
| $111.93 | +0.04 | 0.0% | $110.70 | $112.97 | $106.67 | 141,900 | |
| $111.89 | -2.05 | -1.8% | $112.85 | $113.99 | $109.14 | 221,500 | |
| $113.94 | +0.22 | +0.2% | $113.80 | $117.50 | $112.45 | 142,800 | |
| $113.72 | +2.90 | +2.6% | $111.26 | $114.75 | $108.22 | 123,800 | |
| $110.82 | -0.54 | -0.5% | $113.11 | $114.79 | $108.84 | 133,188 | |
| $111.36 | +3.64 | +3.4% | $106.99 | $113.47 | $104.48 | 239,187 | |
| $107.72 | -3.16 | -2.8% | $111.98 | $113.46 | $105.42 | 176,400 | |
| $110.88 | -12.96 | -10.5% | $122.01 | $122.60 | $110.84 | 208,100 |
Splits
1 split · NASDAQ:MNPR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-5 | Consolidation |
- Ticker
- NASDAQ:MNPR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Latest deck · Nov 8, 2026
AASLD The Liver Meeting 2026
Conference · 19 slides
Latest news
Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Nov 12, 2026
Closed $72.68 (+1.3%) on Nov 12, 2026
Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026
Nov 9, 2026
Closed $73.75 (+3.3%) on Nov 9, 2026
Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data
Nov 2, 2026
Closed $66.28 (-5.7%) on Nov 2, 2026
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
Aug 19, 2026
Closed $123.84 (+4.0%) on Aug 19, 2026
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 13, 2026
Closed $110.41 (-3.9%) on Aug 13, 2026
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
Jul 22, 2026
Closed $112.48 (-1.0%) on Jul 22, 2026
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
Jul 20, 2026
Closed $105.90 (-4.7%) on Jul 20, 2026
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Jun 26, 2026
Closed $94.56 (+7.8%) on Jun 29, 2026
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
Jun 1, 2026
Closed $64.40 (-1.0%) on Jun 1, 2026
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 14, 2026
Closed $60.99 (-0.7%) on May 14, 2026
Monopar Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 14 in the last 12 months · 137 in all · newest Nov 12, 2026 · oldest 2019
- Decks
- 9 decks · latest Nov 8, 2026
Where Monopar Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MNPR · Home listing · This page | NASDAQ | United States | USD |
| Tradegate:1IY0 | Tradegate | Germany | EUR |
| LS Exchange:A40JML | LS Exchange | Germany | EUR |
| gettex:1IY0 | gettex | Germany | EUR |
| Lang & Schwarz:A40JML | Lang & Schwarz | Germany | EUR |
| BOATS:MNPR | BOATS | United States | USD |
| Frankfurt:1IY0 | Frankfurt | Germany | EUR |
| Munich:1IY0 | Munich | Germany | EUR |
| Stuttgart:1IY0 | Stuttgart | Germany | EUR |
Valuation
Price/book 3.7× against a median of 2.5×: 8th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $362.8M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 3.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.18
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Monopar Therapeutics Inc. · NASDAQ:MNPR | US$467.6M | US$362.8M | n/a | n/a | n/a | 3.7× | n/a | 0.0× | 1.18 |
| TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872 | US$489.2M | US$391.6M | n/a | n/a | n/a | 5.0× | n/a | 0.1× | n/a |
| Crescent Biopharma, Inc. · NASDAQ:CBIO | US$482.9M | US$196.0M | n/a | 13.1× | n/a | 1.8× | −727.6% | 0.0× | 0.92 |
| Sana Biotechnology, Inc. · NASDAQ:SANA | US$476.4M | US$408.5M | n/a | n/a | n/a | 2.6× | n/a | 0.3× | 2.29 |
| Regenxbio Inc. · NASDAQ:RGNX | US$473.4M | US$289.0M | n/a | 1.9× | n/a | 3.2× | −113.9% | 0.5× | 1.60 |
| BlossomHill Therapeutics, Inc. · NASDAQ:BLSM | US$461.2M | US$259.4M | n/a | n/a | n/a | 2.2× | n/a | 0.1× | n/a |
| Neurogene Inc. · NASDAQ:NGNE | US$458.5M | US$106.4M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.47 |
| Assembly Biosciences, Inc. · NASDAQ:ASMB | US$454.4M | US$142.3M | n/a | 2.1× | n/a | 1.5× | −16.6% | 0.0× | 1.00 |
| Shattuck Labs, Inc. · NASDAQ:STTK | US$454.2M | US$260.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.10 |
| G2GBIO, Inc. · KRX:456160 | US$449.1M | US$289.0M | n/a | 176× | n/a | 4.3× | −793.7% | 0.0× | n/a |
| DiaMedica Therapeutics Inc. · NASDAQ:DMAC | US$445.1M | US$410.4M | n/a | n/a | n/a | 15.5× | n/a | 0.0× | 1.67 |
| Median of the others | US$459.9M | US$274.7M | 7.6× | 2.5× | −420.7% | 0.0× | 1.47 |
Forecasts
8 strong buy · 4 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 129.92 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.02 · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Chandler D. Robinson | Co-Founder, Chief Executive Officer and Board Member |
| Quan Vu | Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer |
| Andrew Cittadine | Chief Operating Officer |
| Jeffrey D. Kent | Executive Vice President, Head of Medical Affairs |
| Christopher M. Starr | Co-Founder and Executive Chairman of the Board |
| Patrice Rioux | Acting Chief Medical Officer |
| Susan Rodriguez | Chief Commercial and Strategy Officer |
Board
| Director | Role |
|---|---|
| Christopher M. Starr | Co-Founder and Executive Chairman of the Board |
| Chandler D. Robinson | Co-Founder, Chief Executive Officer and Board Member |
| Kim R. Tsuchimoto | Board Member |
| Lavina Talukdar | Board Member |
| Nicole Sweeny | Board Member |
| Raymond W. Anderson | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | +1.3% |
| Q2 2026 | Aug 12, 2026 · Before open | +0.4% |
| Q1 2026 | May 15, 2026 | −7.8% |
| Q4 2025 | Mar 27, 2026 · After close | −1.5% |
| Q3 2025 | Nov 13, 2025 · Before open | +5.4% |
| Q2 2025 | Aug 12, 2025 · Before open | +14.6% |
| Q1 2025 | May 13, 2025 · Before open | −3.6% |
| Q4 2024 | Mar 26, 2025 · Before open | +1.4% |
| Q3 2024 | Nov 8, 2024 · Before open | +7.3% |
| Q2 2024 | Aug 9, 2024 · Before open | −19.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | −5.2% |
| Q4 2023 | Mar 28, 2024 · Before open | −7.6% |
| Q3 2023 | Nov 9, 2023 · Before open | −3.0% |
| Q2 2023 | Aug 10, 2023 · Before open | +3.2% |
| Q1 2023 | May 11, 2023 · Before open | −6.6% |
| Q4 2022 | Mar 23, 2023 · Before open | +0.6% |
| Q3 2022 | Nov 10, 2022 · Before open | −24.8% |
| Q2 2022 | Aug 11, 2022 · Before open | +0.3% |
| Q1 2022 | May 12, 2022 · Before open | −8.0% |
| Q4 2021 | Mar 24, 2022 · Before open | −1.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| AASLD The Liver Meeting 2026 | Conference | 19 slides | Nov 8, 2026 |
| Investor Presentation (November 2026) | Investor deck | 38 slides | November 2026 |
| EASL Congress 2026 | Conference | 16 slides | May 2026 |
| Investor Presentation (May 2026) | Investor deck | 37 slides | May 2026 |
| American Academy of Neurology (AAN) 2026 | Conference | 10 slides | April 2026 |
| AASLD 2025 | Conference | 26 slides | November 2025 |
| ANA 2025 | Conference | 14 slides | September 2025 |
| EANM 2024 | Conference | 13 slides | October 2024 |
| MASCC/ISOO Annual Meeting 2021 | Conference | 18 slides | Jun 24, 2021 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 122.4K | 0 | 0 | 0 | 0 |
| Gross profit | 122.4K | |||||||||
| Research and development | 9.90M | 13.0M | 5.60M | 7.59M | 6.49M | 4.07M | 1.97M | 1.77M | 935.3K | 280.4K |
| Selling, general and administrative | 6.80B | 3.16M | 3.23M | 2.95M | 2.63M | 2.44M | 2.36M | 1.63M | 1.17M | 912.5K |
| Operating income | -16.7M | -16.2M | -8.83M | -10.5M | -9.13M | -6.51M | -4.32M | -3.33M | -16.6M | -1.19M |
| Depreciation and amortization | 716.5M | 16.2M | 8.83M | 21.2K | 48.0K | 6.51M | 4.32K | 3.33M | 2.10M | 1.19M |
| EBITDA | 699.8M | 279 | -235 | -10.5M | -9.08M | 0 | -4.32M | 0 | -14.5M | 0 |
| Interest expense | 21.2K | 24.0K | 81.9K | 98.9K | 103.2K | 48.3K | 7.23K | |||
| Income before tax | -13.7M | -15.6M | -8.40M | -10.5M | -9.10M | -6.30M | -4.22M | -3.30M | -16.6M | -1.19M |
| Income tax | 800 | 800 | 800 | 800 | 0 | 18.4K | 0 | -70.8K | -3.56K | 800 |
| Net income | -13.7M | -15.6M | -8.40M | -10.5M | -9.10M | -6.30M | -4.22M | -3.23M | -16.6M | -1.19M |
| Earnings per share, basic | -1.85 | -4.11 | -3.04 | -0.83 | -0.73 | -0.58 | -0.45 | -0.35 | -1.89 | |
| Earnings per share, diluted | -0.73 | -0.58 | -0.45 | -0.35 | -1.89 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 61.8M | 45.8M | 7.27M | 8.19M | 20.3M | 16.7M | 13.2M | 6.89M | 8.98M | 2.07M |
| Short-term investments | 60.9M | 45.5M | 6.54M | 12.2M | 0 | |||||
| Current assets | 140.5M | 60.3M | 7.33M | 13.2M | 20.5M | 16.8M | 13.2M | 7.25M | 9.13M | 2.10M |
| Total assets | 140.7M | 60.3M | 7.35M | 13.2M | 20.5M | 16.9M | 13.4M | 7.32M | 9.93M | 2.90M |
| Accounts payable | 2.74M | 2.25M | 1.76M | 3.13M | 1.58M | 1.18M | 724.2K | 399.6K | 311.9K | 64.5K |
| Current liabilities | 2.74M | 5.25M | 1.76M | 3.13M | 1.58M | 1.18M | 724.2K | 399.6K | 311.9K | 64.5K |
| Total debt | 154.9K | 8.41K | ||||||||
| Total liabilities | 2.89M | 5.25M | 1.76M | 3.14M | 1.58M | 1.18M | 724.2K | 399.6K | 311.9K | 64.5K |
| Shareholders' equity | 137.8M | 55.0M | 5.59M | 10.1M | 18.9M | 15.7M | 12.6M | 6.92M | 9.62M | 2.83M |
| Shares outstanding | 6.69M | 6.10M | 2.98M | 12.9M | 12.6M | 11.5M | 10.6M | 9.29M | 9.29M | 0 |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -12.2M | -6.40M | -7.86M | -7.23M | -7.32M | -4.66M | -3.02M | -2.68M | -2.63M | -1.19M |
| Capital spending | 0 | 0 | -3 | 0 | -1 | -4 | 0 | 0 | 0 | 0 |
| Free cash flow | -12.2M | -6.40M | -7.86M | -7.23M | -7.32M | -4.66M | -3.02M | -2.89M | -2.63M | -1.19M |
| Cash from investing | -63.5M | -14.3M | 4.93M | -4.92M | 0 | |||||
| Cash from financing | 91.6M | 59.3M | 2.03M | 32.9K | 10.9M | 8.18M | 9.35M | -206.3K | 9.54M | 1.26M |
| Share buybacks | -35.0M | 0 | -47 | -77 | -63 | 8.18M | 10.3M | 4.71M | 1.26M | |
| Change in cash | 16.0M | 38.6M | -920.1K | -12.1M | 3.57M | 3.52M | 6.32M | -2.89M | 6.91M | 67.9K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 24, 2026 | Other filings | SEC |
| 4/A · Change in ownership, amended | Aug 28, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 25, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| S-8 POS | Jul 22, 2026 | Offer document | SEC |
| S-8 POS | Jul 22, 2026 | Offer document | SEC |
| S-8 POS | Jul 22, 2026 | Offer document | SEC |
| S-8 POS | Jul 22, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jul 22, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 22, 2026 | Current report | SEC |
| 144/A · Notice of proposed sale, amended | Jul 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2026 | Current report | SEC |
| 8-K · Current report | Jun 26, 2026 | Current report | SEC |
| 8-K · Current report | Jun 23, 2026 | Meeting outcome | SEC |
| 8-K · Current report | May 29, 2026 | Current report | SEC |
| 8-K · Current report | May 19, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 10-K/A · Annual report, amended | Apr 1, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2026 | Results | SEC |
| 10-K · Annual report | Mar 27, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 2, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 19, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 26, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 24, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 24, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Sep 24, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 15, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 5, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 4, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 29, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| UPLOAD · Letter from the SEC | Jul 25, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jul 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2025 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | May 23, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| ARS · Annual report to shareholders | May 9, 2025 | Annual report | SEC |
| 8-K · Current report | May 7, 2025 | Current report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 2, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Mar 31, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 3, 2025 | Management or board change | SEC |
| 8-K · Current report | Feb 24, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jan 28, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Jan 27, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 23, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 22, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jan 15, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 23, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Dec 23, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Dec 18, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 18, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 17, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 6, 2024 | Current report | SEC |
| S-3 · Registration statement | Nov 29, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 8, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Nov 6, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 31, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 30, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Oct 29, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Oct 28, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Oct 28, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 24, 2024 | Acquisition or disposal | SEC |
| 8-K · Current report | Oct 22, 2024 | Current report | SEC |
| 8-K · Current report | Oct 15, 2024 | Current report | SEC |
| 8-K · Current report | Oct 7, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 12, 2024 | Current report | SEC |
| 8-K · Current report | Aug 27, 2024 | Current report | SEC |
| 8-K · Current report | Aug 21, 2024 | Current report | SEC |
| 8-K · Current report | Aug 14, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Jul 22, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 22, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 11, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jul 9, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2024 | Current report | SEC |
| 8-K · Current report | Jun 10, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 8-K · Current report | May 24, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
This page holds 200 of 539 filings. Open Filings
Cap table
Built by 6ix from Monopar Therapeutics Inc.’s releases · as of Oct 31, 2026
- Common shares
- 6,776,773
- Fully diluted
- 6,776,773
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 6,776,773 | Oct 31, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 31, 2026 | 6,776,773 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Susan Rodriguez Other companies: Avadel Pharmaceuticals PLC (Chief Operating Officer · Since at least May 13, 2025); Veradigm Inc. (Director · Since at least Feb 17, 2023); Heron Therapeutics, Inc. (Director · Sep 20, 2021 – Jan 31, 2025 · Past); Ardelyx, Inc. (Chief Commercial Officer · May 18, 2020 – May 21, 2024 · Past) | Chief Commercial and Strategy Officer · Since at least Mar 2, 2026 |
| Nicole Sweeny Other companies: KalVista Pharmaceuticals, Inc. (Chief Commercial Officer · Since at least Jun 18, 2025); Praxis Precision Medicines, Inc. (Chief Commercial Officer · Oct 15, 2020 – Feb 12, 2023 · Past) | Board Member · Since at least Jun 22, 2026 |
| Quan Vu Other companies: Ocugen, Inc. (CFO/CBO · Mar 6, 2023 – Mar 6, 2023 · Past); Forum Markets, Incorporated (COO / Chief Business Officer · Oct 29, 2021 – Dec 16, 2021 · Past) | Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer · Since at least Mar 3, 2025 |
| Andrew Paul Mazar Other companies: Actuate Therapeutics, Inc. (Chief Operating Officer · Since at least Aug 12, 2024) | Chief Scientific Officer, Director · Jan 8, 2018 – Mar 31, 2022 · Past |
| Christopher M. Starr Other companies: Raptor Pharmaceutical Corp (Director · Sep 29, 2009 – Oct 24, 2016 · Past) | Co-Founder and Executive Chairman of the Board · Since at least Jan 8, 2018 |
| Karthik Radhakrishnan Other companies: Acer Therapeutics Inc (Chief Financial Officer · Mar 29, 2013 – Apr 8, 2015 · Past) | Chief Financial Officer · Jul 1, 2024 – Oct 28, 2024 · Past |
| Michael J. Brown Other companies: Euronet Worldwide, Inc. (Chairman and CEO · Since at least Oct 13, 2023) | Director · Sep 30, 2023 – Dec 31, 2023 · Past |
| Raymond W. Anderson Other companies: Raptor Pharmaceutical Corp (Director · Sep 29, 2009 – Oct 24, 2016 · Past) | Board Member · Since at least Jan 8, 2018 |
| Andrew Cittadine | Chief Operating Officer · Since at least Jun 1, 2021 |
| Arthur J Klausner | Director · Since at least Mar 31, 2022 |
All 17 people
| Person | Seat |
|---|---|
| Chandler D. Robinson | Chief Executive Officer, Director · Since at least Jan 8, 2018 |
| Jeffrey D. Kent | Executive Vice President, Head of Medical Affairs · Since at least Aug 19, 2026 |
| Jose Octavio Pinto Costa Filho | Chief Medical Officer · Jul 12, 2021 – Jul 12, 2021 · Past |
| Kim R. Tsuchimoto | Board Member · Since at least Jan 8, 2018 |
| Kirsten Anderson | SVP, Clinical Development · Jan 8, 2018 – Jan 8, 2018 · Past |
| Lavina Talukdar | Director · Since at least Feb 21, 2025 |
| Patrice Rioux | Acting Chief Medical Officer · Since at least Aug 27, 2026 |
Log in to ask 6ix AI your own questions about Monopar Therapeutics Inc.